Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Total Liabilities (2016 - 2025)

Enanta Pharmaceuticals' Total Liabilities history spans 14 years, with the latest figure at $202.9 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 14.32% year-over-year to $202.9 million; the TTM value through Dec 2025 reached $202.9 million, down 14.32%, while the annual FY2025 figure was $216.0 million, 12.84% down from the prior year.
  • Total Liabilities reached $202.9 million in Q4 2025 per ENTA's latest filing, down from $216.0 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $257.3 million in Q2 2023 to a low of $31.7 million in Q1 2021.
  • Average Total Liabilities over 5 years is $150.2 million, with a median of $209.5 million recorded in 2025.
  • Peak YoY movement for Total Liabilities: fell 16.92% in 2022, then skyrocketed 445.34% in 2023.
  • A 5-year view of Total Liabilities shows it stood at $56.2 million in 2021, then decreased by 16.92% to $46.7 million in 2022, then skyrocketed by 406.7% to $236.6 million in 2023, then grew by 0.09% to $236.8 million in 2024, then decreased by 14.32% to $202.9 million in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Total Liabilities are $202.9 million (Q4 2025), $216.0 million (Q3 2025), and $221.8 million (Q2 2025).